Table 3.
Comparison of efficacy between nedaplatin and cisplatin in treating MPE
| Cisplatin group (n=109) |
Nedaplatin group (n=110) |
P-value | |
|---|---|---|---|
| Lung cancer, n (%) | 0.072 | ||
| CR | 17 (29.82) | 24 (41.38) | |
| PR | 9 (15.79) | 10 (17.24) | |
| SD | 12 (21.05) | 14 (24.14) | |
| PD | 19 (33.33) | 10 (17.24) | |
| Breast cancer, n (%) | 0.767 | ||
| CR | 9 (37.50) | 10 (35.71) | |
| PR | 7 (29.17) | 11 (39.29) | |
| SD | 5 (20.83) | 4 (14.29) | |
| PD | 3 (12.50) | 3 (10.71) | |
| Gastrointestinal cancer, n (%) | 0.686 | ||
| CR | 8 (28.57) | 9 (37.50) | |
| PR | 8 (28.57) | 5 (20.83) | |
| SD | 8 (28.57) | 7 (29.17) | |
| PD | 4 (14.29) | 3 (12.50) | |
| All cancers, n (%) | 0.081 | ||
| CR | 34 (31.19) | 43 (39.09) | |
| PR | 24 (22.02) | 26 (23.64) | |
| SD | 25 (22.94) | 25 (22.73) | |
| PD | 26 (23.85) | 16 (14.55) | |
| Overall response, n (%) | 58 (53.21) | 69 (62.73) | 0.154 |
Abbreviations: CR, complete remission; MPE, malignant pleura effusion; PD, progressive disease; PR, partial remission; SD, stable disease.